EFFECT OF DALCETRAPIB PLUS PRAVASTATIN ON LIPOPROTEIN METABOLISM IN DYSLIPIDEMIC PATIENTS: RESULTS OF A PHASE 2B DOSE-RANGING STUDY  by Ballantyne, Christie M. et al.
A47.E444
JACC March 9, 2010
Volume 55, issue 10A
 HYPERTENSION, LIPIDS AND PREVENTION 
EFFECT OF DALCETRAPIB PLUS PRAVASTATIN ON LIPOPROTEIN METABOLISM IN DYSLIPIDEMIC 
PATIENTS: RESULTS OF A PHASE 2B DOSE-RANGING STUDY
ACC Oral Contributions
Georgia World Congress Center, Room B408
Monday, March 15, 2010, 8:00 a.m.-8:15 a.m.
Session Title: What’s New About High-Density Lipoprotein?
Abstract Category: Pharmacology/Hormones/Lipids—Clinical
Presentation Number: 0904-03
Authors: Christie M. Ballantyne, Michael Miller, Eric J. Niesor, Tracy Burgess, David Kallend, Evan A. Stein, Baylor College of Medicine, Houston, TX, 
Hoffman-LaRoche Ltd, Basel, Switzerland
Background: As reported earlier, adding the cholesterol ester transfer protein inhibitor dalcetrapib to pravastatin for 12 wk in dyslipidemic 
patients significantly raised mean high-density lipoprotein cholesterol (HDL-C) levels by up to 36% and apoA-1 by up to 15% in a Phase 2b trial.
Methods: In this same multicenter, randomized, double-blind study, patients with <50 mg/dL HDL-C on 40 mg/d pravastatin received placebo 
(n=73) or 300 (n=75), 600 (n=67) or 900 (n=72) mg/d dalcetrapib for 12 wk. The % changes from baseline to 12 wk in lipoprotein profile and in 
HDL and low-density lipoprotein (LDL) subclasses were assessed using nuclear magnetic resonance (NMR) and gradient gel electrophoresis (GGE).
Results: NMR and GGE both showed a shift in the lipoprotein profile at 12 wk in all treatment arms for both HDL and LDL particles. The % of large 
HDL particles increased with increasing dalcetrapib dose. The % of large LDL particles also increased; this was independent of dose with NMR but 
dose-dependent with GGE. The table shows the % change from baseline to 12 wk in the middle-dose group for selected HDL efficacy parameters. 
After precipitation, ApoE increased in the HDL fraction (unchanged in total plasma) and cholesterol free/ester ratio did not change.
Secondary
Efficacy Parameter
% Change, Baseline - Week 12, 600 mg dalcetrapib
NMR Electrophoresis
HDL particles (total) +10.9 ----
HDL large +171.3 ----
HDL medium +69.6 ----
HDL small +2.4 ----
HDL 2a ---- +10.1
HDL 2b ---- +30.1
HDL 3a ---- -6.7
HDL 3b ---- -13.9
HDL 3c ---- -14.6
Conclusions: Adding dalcetrapib to pravastatin beneficially modified the atherogenic lipoprotein profile in dyslipidemic patients. ApoE is 
redistributed from very low density lipoprotein/LDL to HDL particles, which may facilitate cholesterol delivery to the liver.
